Overview
- Editors:
-
-
Yong-Ku Kim
-
Department of Psychiatry, Korea University Ansan Hospital, College of Medicine, Ansan, Korea (Republic of)
- Explains insights offered by a network science perspective
- Examines important diagnostic and neurobiological issues
- Discusses the full array of current and emerging treatments
Access this book
Other ways to access
Table of contents (27 chapters)
-
-
Re-thinking Depression from a Network Perspective
-
-
-
-
- Taolin Chen, Ziqi Chen, Qiyong Gong
Pages 35-55
-
- Kyoung-Sae Na, Yong-Ku Kim
Pages 57-69
-
-
- Kyu-Man Han, Byung-Joo Ham, Yong-Ku Kim
Pages 85-99
-
Current Diagnostic and Neurobiological Issues
-
Front Matter
Pages 101-101
-
- Seon-Cheol Park, Yong-Ku Kim
Pages 103-116
-
- Kathleen Saavedra, Luis A. Salazar
Pages 117-128
-
- Leszek Rudzki, Michael Maes
Pages 129-155
-
-
- Matea Nikolac Perkovic, Marina Sagud, Lucija Tudor, Marcela Konjevod, Dubravka Svob Strac, Nela Pivac
Pages 175-202
-
- Pinar Unal-Aydin, Orkun Aydin, Ayla Arslan
Pages 203-230
-
- Farhana Islam, Ilona Gorbovskaya, Daniel J. Müller
Pages 231-255
-
- Meysam Amidfar, Gislaine Zilli Réus, Airam Barbosa de Moura, João Quevedo, Yong-Ku Kim
Pages 257-272
-
Current Specific Treatments for Depression
-
Front Matter
Pages 273-273
-
- Klaus Mathiak, Micha Keller
Pages 275-293
-
- Sang-Hyuk Lee, Sung Joon Cho
Pages 295-310
About this book
This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.
Editors and Affiliations
-
Department of Psychiatry, Korea University Ansan Hospital, College of Medicine, Ansan, Korea (Republic of)
Yong-Ku Kim
About the editor
Yong-Ku Kim, MD, PhD is a Professor of Psychiatry at College of Medicine, Korea University. He received a MD degree from College of Medicine, Korea University in 1987 and a PHD in psychiatry from Korea University in 1998. Dr. Kim has been affiliated with Korea University since 1998, first as an assistant professor (1998-2000), then as associated professor (2001-2005), professor (2006- present). For the past 20 years, his professional activities have extended beyond the area of pure clinical or research work. Dr. Kim has well over 200 publications in peer-reviewed international journals, including Biological Psychiatry, Molecular Psychiatry, Clinical Journal of Psychiatry, and Progress in Neuropsychopharmacology and Biological Psychiatry and 30 publications of book chapters and have made over 90 academic presentations in my area of interest. Dr. Kim is a fellow of Collogicum Internationale Neuropsychopharmacologicum, International Society for Affective Disorders, World Federation of theSociety of biological Psychiatry. He currently sits on the editorial boards of some leading academic journals in the field of neurobiology, including Progress in Neuropsychopharmacology and Biological Psychiatry, Psychiatry Investigation, World Journal Psychiatry, Annals of Depression and Anxiety, Psychiatry Journal and so on. Dr. Kim received prestigious awards such as Astrageneca Award and Dr. Paul Janssen Schizophrenia Research Award.
